Apyx Medical Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $106.6M
- Price
- $2.53
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.78%
- Volume
- 5.0K
About
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Quick stats
Shares outstanding42.1M
Computed float39.6M
Float / shares93.9%
Cash runway (months)20.4
Key info
SectorHealthcare
IndustryMedical - Specialties
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000719135
Websitehttps://apyxmedical.com
AI Summary
AI-generated1/15
minorbullishclinical trial
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality
Apyx Medical announced a prospective clinical study, published in Plastic and Reconstructive Surgery - Global Open, showing Renuvion helium plasma treatment produced measurable biological changes in skin quality.
At Day 180, treated tissue showed 30% greater elastin fiber density, 55% higher elastin staining intensity, and 34% less inflammation versus control tissue, with all six completing participants reporting improvement and satisfaction.
The study is small (seven facelift patients at two U.S. sites), but management says it supports the position that Renuvion should be part of every liposuction procedure worldwide.
Red flags
- Very small sample size (n=7, n=6 completing Day 180) limits statistical significance of findings